Translational and Regulatory Sciences
Online ISSN : 2434-4974
Advance online publication
Displaying 1-3 of 3 articles from this issue
  • Gen SATO, Mikio NAKAJIMA, Kuniyoshi SAKAI, Yuko TOGASHI, Masakatsu YAM ...
    Article ID: 2023-009
    Published: 2024
    Advance online publication: March 20, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML ADVANCE PUBLICATION

    In recent years, introducing virtual control groups (VCGs) into toxicology studies is increasingly discussed because of the 3Rs and non-human primate (NHP) supply issues. Evaluating toxicology study results using historical control data is not new; however, introducing a VCG means replacing the concurrent control group in a toxicology study with a VCG, thereby reducing the number of animals used by approximately 30%. While it may be possible to conduct a toxicology study of a developmental compound in which the concurrent control group is replaced with a VCG, the scientific appropriateness of introducing a VCG and its regulatory acceptability needs to be considered. Therefore, we identified the following five issues that may arise when implementing a VCG: 1) regulatory requirements, 2) common issues when introducing a VCG, 3) issues related to histopathological examinations when introducing a VCG, 4) statistical analysis when introducing a VCG, and 5) facility monitor (sentinel) animals. Current regulatory guidelines require a concurrent control group for a pivotal toxicology study, whose results, if do not meet the requirements of these guidelines, cannot be used for new drug approval applications. Even if the use of VCGs is justified from animal welfare and scientific points of view, it is critical that the industry work with health authorities to ensure that data from these studies are accepted. The Japan Pharmaceutical Manufacturers Association will continue to hold necessary discussions with key stakeholders to accelerate efficient and effective new drug development pertaining to the use of VCGs.

  • Shimako TANAKA, Satoshi MIYATA, Jun YAMATO, Shun KUMAGAI, Masaki KOGAW ...
    Article ID: 2024-001
    Published: 2024
    Advance online publication: March 20, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML ADVANCE PUBLICATION

    Medication history is a series of data for each patient recorded by pharmacists in daily clinical practice in Japanese pharmacies. This real-world data potentially contains useful information on various risks induced by drugs; however, this information has rarely been used. Therefore, we aimed to verify whether medication histories can be used for drug-induced risk assessment by comparing them with known events as references. To this end, we chose previously reported large-scale trials indicating that anticholinergic drugs for overactive bladder (OAB) are associated with the risk of inducing dementia. We referred to these studies and conducted a retrospective study based on the medication histories of 172,958 patients aged 55 years or older visiting a community pharmacy. Six drugs for OAB (oxybutynin, propiverine, tolterodine, fesoterodine, solifenacin, and imidafenacin) were tested for their risk of inducing dementia, which was determined at the start of using one of the four drugs for dementia (donepezil, galantamine, rivastigmine, and memantine). The association between OAB medications and dementia was assessed using odds ratios (ORs) and 95% confidence intervals (95% CIs). The analysis included 2,634 patients in the case group and 170,324 patients in the control group. A significant difference was observed between the case and control groups (OR, 2.12; 95% CI, 1.66–2.67), indicating that anticholinergic drugs increased the risk of developing dementia. The results were equivalent to those of the referenced large-scale clinical trials, suggesting that medication histories are useful for drug-induced risk assessment.

  • Hiroki ISHIKAWA, Masato HIROTA, Miho TAMAI
    Article ID: 2023-008
    Published: 2024
    Advance online publication: February 22, 2024
    JOURNAL OPEN ACCESS FULL-TEXT HTML ADVANCE PUBLICATION

    The effectiveness of vaccines in preventing infection from specific pathogens is closely related to the magnitude of the antigen-specific T cell and antibody responses induced by the vaccine. These responses depend on the immune states of the individual, which is shaped by genetic and environmental factors. Recent studies using omics technologies identified immune cells, genes, and gut microbial species and metabolic pathways at baseline or during early vaccine responses as correlates of vaccine responses. These findings shed light on the molecular and cellular mechanisms underlying the inter-individual differences in vaccine responses. In this review, we provide an overview of correlates of recently developed COVID-19 mRNA vaccine-induced adaptive immune responses.

feedback
Top